BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 38668070)

  • 1. Multimodal Approaches to Patient Selection for Pancreas Cancer Surgery.
    Muaddi H; Kearse L; Warner S
    Curr Oncol; 2024 Apr; 31(4):2260-2273. PubMed ID: 38668070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
    Kim NH; Kim HJ
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using Molecular Subtyping of Pancreatic Ductal Adenocarcinoma for Multimodal Treatment Selection in Resectable Disease.
    Dima SO; Dumitraşcu T; Popescu I; Duda DG
    Chirurgia (Bucur); 2022 Jun; 117(4):407-414. PubMed ID: 36049097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals.
    Kulkarni NM; Mannelli L; Zins M; Bhosale PR; Arif-Tiwari H; Brook OR; Hecht EM; Kastrinos F; Wang ZJ; Soloff EV; Tolat PP; Sangster G; Fleming J; Tamm EP; Kambadakone AR
    Abdom Radiol (NY); 2020 Mar; 45(3):729-742. PubMed ID: 31768594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular Resections for Pancreatic Ductal Adenocarcinoma: Vascular Resections for PDAC.
    Oba A; Bao QR; Barnett CC; Al-Musawi MH; Croce C; Schulick RD; Del Chiaro M
    Scand J Surg; 2020 Mar; 109(1):18-28. PubMed ID: 31960765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resection of metachronous pancreatic cancer 4 years after pancreaticoduodenectomy for stage III pancreatic adenocarcinoma.
    Hamner JB; White M; Crowder C; Singh G
    World J Surg Oncol; 2015 Sep; 13():290. PubMed ID: 26419361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma.
    Van den Broeck A; Sergeant G; Ectors N; Van Steenbergen W; Aerts R; Topal B
    Eur J Surg Oncol; 2009 Jun; 35(6):600-4. PubMed ID: 19131205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
    Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
    Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.
    Soloff EV; Zaheer A; Meier J; Zins M; Tamm EP
    Abdom Radiol (NY); 2018 Feb; 43(2):301-313. PubMed ID: 29198002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New challenges in perioperative management of pancreatic cancer.
    Puleo F; Maréchal R; Demetter P; Bali MA; Calomme A; Closset J; Bachet JB; Deviere J; Van Laethem JL
    World J Gastroenterol; 2015 Feb; 21(8):2281-93. PubMed ID: 25741134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection.
    Murakawa M; Kawahara S; Takahashi D; Kamioka Y; Yamamoto N; Kobayashi S; Ueno M; Morimoto M; Sawazaki S; Tamagawa H; Ohshima T; Yukawa N; Rino Y; Morinaga S
    World J Surg Oncol; 2023 Aug; 21(1):263. PubMed ID: 37620940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
    Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
    Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
    Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma.
    Sakaguchi T; Satoi S; Yamamoto T; Yamaki S; Sekimoto M
    Surg Today; 2020 Apr; 50(4):335-343. PubMed ID: 31993761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection criteria in resectable pancreatic cancer: a biological and morphological approach.
    Tamburrino D; Partelli S; Crippa S; Manzoni A; Maurizi A; Falconi M
    World J Gastroenterol; 2014 Aug; 20(32):11210-5. PubMed ID: 25170205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy.
    Yang HK; Park MS; Han K; Eom G; Chung YE; Choi JY; Bang S; Kang CM; Seong J; Kim MJ
    Cancer Res Treat; 2024 Jan; 56(1):247-258. PubMed ID: 37605535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection].
    Ridwelski K; Meyer F; Schmidt U; Lippert H
    Zentralbl Chir; 2005 Aug; 130(4):353-61. PubMed ID: 16103961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preoperative chemoradiotherapy.
    Murata Y; Ogura T; Hayasaki A; Gyoten K; Ito T; Iizawa Y; Fujii T; Tanemura A; Kuriyama N; Kishiwada M; Sakurai H; Mizuno S
    PLoS One; 2022; 17(4):e0264573. PubMed ID: 35377885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study.
    Nakano Y; Kitago M; Shinoda M; Abe Y; Yagi H; Hibi T; Takeuchi A; Aiura K; Itano O; Kitagawa Y
    Cancer Med; 2017 Oct; 6(10):2278-2286. PubMed ID: 28925039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary strategies to improve the outcome in locally advanced pancreatic cancer.
    Schneider R; Späth C; Nitsche U; Erkan M; Kleeff J
    Minerva Chir; 2017 Oct; 72(5):424-431. PubMed ID: 28565894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.